Wedbush Issues Pessimistic Estimate for Ardelyx Earnings

Ardelyx, Inc. (NASDAQ:ARDX - Free Report) - Wedbush lowered their Q2 2025 earnings estimates for shares of Ardelyx in a note issued to investors on Tuesday, July 15th. Wedbush analyst L. Chico now anticipates that the biopharmaceutical company will post earnings per share of ($0.09) for the quarter, down from their previous estimate of ($0.08). The consensus estimate for Ardelyx's current full-year earnings is ($0.18) per share. Wedbush also issued estimates for Ardelyx's Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.32) EPS.

Ardelyx (NASDAQ:ARDX - Get Free Report) last released its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.07). Ardelyx had a negative net margin of 14.86% and a negative return on equity of 34.45%. The firm had revenue of $74.11 million during the quarter, compared to the consensus estimate of $79.40 million. During the same period in the prior year, the business posted ($0.11) earnings per share. Ardelyx's quarterly revenue was up 61.1% compared to the same quarter last year.

A number of other research firms also recently weighed in on ARDX. HC Wainwright initiated coverage on Ardelyx in a report on Wednesday, June 18th. They set a "buy" rating and a $10.00 target price for the company. Wall Street Zen downgraded Ardelyx from a "hold" rating to a "sell" rating in a research note on Monday, May 5th. Citigroup reduced their target price on Ardelyx from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Finally, Raymond James Financial lowered Ardelyx from a "strong-buy" rating to an "outperform" rating and set a $11.00 price target on the stock. in a research note on Friday, May 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $10.89.

Ardelyx Stock Performance

ARDX stock traded down $0.11 during midday trading on Thursday, reaching $4.41. 3,246,910 shares of the company were exchanged, compared to its average volume of 4,416,540. The company has a debt-to-equity ratio of 1.04, a current ratio of 4.12 and a quick ratio of 3.81. The business has a 50-day moving average price of $3.92 and a two-hundred day moving average price of $4.71. Ardelyx has a one year low of $3.21 and a one year high of $7.18. The firm has a market capitalization of $1.06 billion, a price-to-earnings ratio of -20.05 and a beta of 0.60.

Insiders Place Their Bets

In related news, CFO Justin A. Renz sold 7,218 shares of the stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $4.08, for a total value of $29,449.44. Following the completion of the sale, the chief financial officer directly owned 416,089 shares of the company's stock, valued at approximately $1,697,643.12. This represents a 1.71% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Mike Kelliher sold 14,522 shares of the company's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $4.08, for a total value of $59,249.76. Following the completion of the transaction, the insider owned 282,158 shares of the company's stock, valued at $1,151,204.64. This trade represents a 4.89% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders bought 881,377 shares of company stock worth $3,402,411 and sold 125,143 shares worth $517,667. 4.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ARDX. Wealth Enhancement Advisory Services LLC boosted its position in shares of Ardelyx by 21.9% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 65,030 shares of the biopharmaceutical company's stock valued at $278,000 after acquiring an additional 11,694 shares during the last quarter. Harbor Capital Advisors Inc. increased its stake in Ardelyx by 79.6% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 233,248 shares of the biopharmaceutical company's stock worth $914,000 after purchasing an additional 103,385 shares during the period. Rhumbline Advisers increased its stake in Ardelyx by 4.1% in the 1st quarter. Rhumbline Advisers now owns 339,436 shares of the biopharmaceutical company's stock worth $1,667,000 after purchasing an additional 13,312 shares during the period. Strs Ohio purchased a new position in shares of Ardelyx during the first quarter valued at approximately $135,000. Finally, Focus Partners Wealth purchased a new position in shares of Ardelyx during the first quarter valued at approximately $72,000. Institutional investors own 58.92% of the company's stock.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.